Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms

Protocol No
ECOG-EA2142
Principal Investigator
Ben George
Phase
II
Summary
The purpose of this study is to compare the effects, both good and bad, of the study drugs temozolomide and capecitabine to the usual chemotherapy treatment for this disease of cisplatin and etoposide. Usually the first treatment given for this cancer is cisplatin and etoposide. The chemotherapy drugs temozolomide and capecitabine are also used to treat this disease but usually not until the first treatment, cisplatin and etoposide, stops working. It is not known if this is the best approach or if the temozolomide and capecitabine should be given first instead. The use of temozolomide and capecitabine could shrink your cancer but it could also cause side effects. For patients who receive the usual treatment for this cancer, it is usually about 6 months before the usual treatment stops working and a different treatment is needed. To be better, the study drugs should increase how long you are able to live with your cancer before you need to switch to different treatment, by 4 months or more compared to the usual approach.
Description
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: